Brokerages forecast that BioScrip, Inc. (NASDAQ:BIOS) will report $171.79 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for BioScrip’s earnings. The lowest sales estimate is $170.49 million and the highest is $173.40 million. BioScrip posted sales of $240.12 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 28.5%. The business is expected to issue its next earnings results on Friday, March 2nd.

According to Zacks, analysts expect that BioScrip will report full year sales of $171.79 million for the current fiscal year, with estimates ranging from $805.10 million to $808.00 million. For the next financial year, analysts anticipate that the company will report sales of $722.13 million per share, with estimates ranging from $695.23 million to $734.93 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for BioScrip.

BioScrip (NASDAQ:BIOS) last announced its quarterly earnings results on Thursday, November 2nd. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). The business had revenue of $198.70 million during the quarter, compared to the consensus estimate of $202.91 million. During the same quarter in the previous year, the business posted ($0.12) EPS. The firm’s revenue was down 11.5% on a year-over-year basis.

Several equities research analysts have recently issued reports on the stock. ValuEngine upgraded shares of BioScrip from a “sell” rating to a “hold” rating in a research note on Monday, August 14th. Zacks Investment Research downgraded shares of BioScrip from a “buy” rating to a “hold” rating in a research note on Monday, August 14th. BidaskClub downgraded shares of BioScrip from a “buy” rating to a “hold” rating in a research note on Thursday, August 17th. SunTrust Banks upgraded shares of BioScrip from a “hold” rating to a “buy” rating and raised their price objective for the stock from $3.25 to $3.75 in a research note on Thursday, August 10th. Finally, Jefferies Group restated a “buy” rating and issued a $4.00 price objective (up previously from $3.00) on shares of BioScrip in a research note on Thursday, August 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $3.60.

Shares of BioScrip (NASDAQ:BIOS) opened at $2.55 on Wednesday. The company has a debt-to-equity ratio of -6.11, a quick ratio of 1.60 and a current ratio of 1.91. BioScrip has a 52 week low of $0.98 and a 52 week high of $3.39.

In other BioScrip news, Director Michael G. Bronfein sold 27,000 shares of BioScrip stock in a transaction on Friday, September 15th. The shares were sold at an average price of $2.69, for a total transaction of $72,630.00. Following the sale, the director now owns 129,669 shares in the company, valued at $348,809.61. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Coliseum Capital Management, L sold 2,846,941 shares of BioScrip stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $2.93, for a total transaction of $8,341,537.13. The disclosure for this sale can be found here. 0.80% of the stock is owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd acquired a new stake in BioScrip during the third quarter worth $114,000. Captrust Financial Advisors acquired a new stake in BioScrip during the second quarter worth $123,000. Voya Investment Management LLC boosted its stake in BioScrip by 41.4% during the second quarter. Voya Investment Management LLC now owns 50,799 shares of the company’s stock worth $138,000 after buying an additional 14,867 shares in the last quarter. Highbridge Capital Management LLC acquired a new stake in BioScrip during the third quarter worth $153,000. Finally, Goldman Sachs Group Inc. boosted its stake in BioScrip by 65.8% during the first quarter. Goldman Sachs Group Inc. now owns 64,257 shares of the company’s stock worth $109,000 after buying an additional 25,500 shares in the last quarter. Hedge funds and other institutional investors own 84.69% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/06/analysts-anticipate-bioscrip-inc-bios-will-post-quarterly-sales-of-171-79-million.html.

BioScrip Company Profile

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get a free copy of the Zacks research report on BioScrip (BIOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.